Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

In this study we investigated a new liposomal hepatitis A vaccine (Epaxal(R)) developed by the Swiss Serum and Vaccine institute clinically and immunologically using a one nose priming schedule and a booster injection after 1 year. This vaccine contains formalin inactivated hepatitis A virus particles attached to phospholipid vesicles together with influenza virus haemagglutinin. Two closes of the vaccine were administered at months 0 and 12 in 117 volunteers, Blood samples were drawn at days -7, 14 and 28 and after 6, 12 and 13 months, local and systemic reactions were monitored by means of questionnaires, Immunogenicity was evaluated as usual by the determination of anti-HAV from the collected sera using the ELISA technique, In order to evaluate the protective efficacy of the vaccine induced antibodies a sample of 25 sera mainly from vaccinees showing low ELISA titres was additionally analysed by means of a virus NT The vaccine was excellently tolerable and highly immunogenic, Seroconversion evaluated by ELISA was 97 and 99%, respectively, 14 and 28 days after the first dose and 100% after-the second dose, NT litres were well correlated with ELISA titres and showed similar seroconversion rates even in the early phase of immunization. The results of this study show that with two closes of the liposomal hepatitis A vaccine administered at months 0 and 12 early protection within 14 days and long lasting immunity can be achieved. (C) 1997 Elsevier Science Ltd.